Introduction {#S0001}
============

Epilepsy, antiepileptic drugs (AEDs), and the reproductive system have complex interactions. Fertility is lower in both men and women with epilepsy than in the general population.^[@CIT0001]--[@CIT0003]^ Moreover, reproductive endocrine disorders are more common among patients with epilepsy than among the normal population.^[@CIT0004]--[@CIT0006]^ While menstrual disorders, polycystic ovaries, and infertility have been described in women,^[@CIT0007]--[@CIT0009]^ reduced potency, diminished libido, erectile dysfunction, lack of sexual satisfaction, and sperm abnormalities have been found in men.^[@CIT0007],\ [@CIT0010],\ [@CIT0011]^ In both sexes, sexual problems^[@CIT0012]^ and endocrine changes have been frequently described in previous studies.^[@CIT0007]--[@CIT0009]^ These disorders have been attributed to both epilepsy itself and AEDs. This study compared sexual function and reproductive hormone levels among male epileptic patients taking various antiepileptic drugs and normal controls.

Materials and Methods {#S0002}
=====================

In this study, 59 male epileptic patients, of whom 18 were on carbamazepine (CBZ), 15 were on sodium valproate (VPA), and 17 were on lamotrigine (LTG), were enrolled. The mean age of participants was 24 ± 5 years. These patients had referred to the outpatient neurology and epilepsy clinics of Isfahan University of Medical Sciences, Iran.

All subjects were epileptic patients (generalized or focal) with idiopathic epilepsy whose diagnosis was made by an expert neurologist at least one year prior to the study. Patients were treated with CBZ, VPA, or LTG and had not changed their AED or its dose over the previous 6 months. Individuals with history of endocrine comorbidity, evidence of diabetes or thyroid dysfunction as determined by fasting serum glucose, thyroid stimulating hormone, and thyroxine (T4) measurements, pituitary abnormality on cranial magnetic resonance imaging (MRI), or evidence of depression as determined by the clinical assessment of a psychiatrist were not included. In addition, patients were not recruited if there was an evidence of anatomical disease of testes such as varicocele, spermatocele, cyst, or occult testicle in the clinical assessment by an urologist. On the other hand, 23 male age-matched subjects who had no known history of diseases were recruited as healthy controls (mean age: 24 ± 4 years). None of the controls had a history of seizures or medical, neurologic, or endocrine illness, and none was receiving medication.

After receiving written informed consents from all subjects, morning blood samples were obtained to assess pituitary hormones including luteinizing hormone (LH), follicle stimulating hormone (FSH), and prolactin (PRL). Gonadal hormones, i.e. testosterone (T) and estradiol (E), sex hormone binding globulin (SHBG), androstenedione (AND), and dehydroepiandrosterone (DHEAS) levels were also determined. Estimate of gonadal efficiency (T/LH) was calculated for each subject. Blood samples were centrifuged. After 20 minutes, the serum was separated and the samples were frozen at -20 degrees centigrade until hormone assays were performed. The examination and measurement of testes were conducted by an urologist. The length, depth, and width of testes were measured using a ruler, a pair of calipers, or ultrasound imaging. In addition, semen analysis was performed in 33 of our cases (about 60%).

The ethics committee of Isfahan University of Medical Sciences approved this study. Quantitative data was expressed as mean and standard deviation (SD). Categorical variables were described by relative frequencies. For comparisons of the quantitative variables the Student\'s t- test was used. Chi-squared test with Pearson modification was used for comparisons between the categorical variables. Intergroup comparisons of the quantitative variables were made by analysis of variance (ANOVA). The statistical significance criterion was set at P \< 0.05.

Results {#S0003}
=======

The mean testicle length, breadth, and height were 4.5 ± 0.5, 2.0 ± 0.5, and 2.5 ± 0.5, respectively. While 27 patients (92%) had normal semen analysis, four cases had reduced motility and sperm count of two cases was zero. The ages of the groups were not significantly different. In addition, the three epileptic patient groups did not significantly differ in duration of epilepsy and frequency of focal or generalized epilepsy ([Table 1](#T0001){ref-type="table"}).

###### 

Age, types of epilepsy, and duration of epilepsy in different groups

  Group              Age (years)   Focal Epilepsy   Generalized Epilepsy   Duration of epilepsy (years)
  ------------------ ------------- ---------------- ---------------------- ------------------------------
  Carbamazepine      25.7 ± 4.7    9 (56.3)         9 (25.0)               7.9 ± 3.1
  Sodium valproate   22.7 ± 5.5    3 (18.8)         14 (38.9)              5.8 ± 3.1
  Lamotrigine        23.4 ± 3.7    4 (25.0)         13 (36.1)              6.4 ± 3.2
  Control            23.8 ± 3.9    \-               \-                     \-

Values are expressed as mean ± SD or n (%).

Hormone test results are shown in [Table 2](#T0002){ref-type="table"}. Men receiving CBZ, VPA, and LTG had significantly lower mean T levels than the control group (P \< 0.01). Subject receiving LTG had significantly higher mean T levels than the CBZ and VPA groups. While the CBZ group had significantly lower DHEAS levels than the other groups (P \< 0.01), there was no significant difference between other groups. Patients who were on VPA had significantly higher mean AND levels than CBZ, LTG, and control groups (P \< 0.01). However, the other groups were not significantly different in this regard. Serum levels of DHEAS in LTG treated group were significantly lower than the CBZ and VPA groups, but were in the same range as controls. The CBZ group had significantly higher mean LH levels compared to the other groups. The LTG group had significantly lower FSH levels than the other groups.

###### 

Serum hormone concentrations in patients who were treated with sodium valproate (VPA), carbamazepine (CBZ), or lamotrigine (LTG) for epilepsy, and in control (CON) subjects

  Hormones                           Medication Groups   Mean ± SD         P
  ---------------------------------- ------------------- ----------------- ---------------------------------------------
  Testosterone                       CBZ                 3.60 ± 1.70       \> 0.05[\*](#TF0001){ref-type="table-fn"}
                                     VPA                 3.30 ± 1.90       \< 0.01[†](#TF0002){ref-type="table-fn"}
                                     LTG                 3.30 ± 1.80       \< 0.01[‡](#TF0003){ref-type="table-fn"}
                                     CON                 6.60 ± 1.90       \< 0.05[§](#TF0004){ref-type="table-fn"}
  Dehydroepiandrosterone sulfate     CBZ                 0.86 ± 0.40       \< 0.01[\*](#TF0001){ref-type="table-fn"}
                                     VPA                 1.80 ± 0.53       \< 0.01[‡](#TF0003){ref-type="table-fn"}
                                     LTG                 1.51 ± 0.41       \> 0.05[†](#TF0002){ref-type="table-fn"}
                                     CON                 1.72 ± 0.39       \> 0.05[§](#TF0004){ref-type="table-fn"}
  Androstenedione                    CBZ                 1.70 ± 0.84       \< 0.05[\*](#TF0001){ref-type="table-fn"}
                                     VPA                 3.21 ± 2.38       \< 0.05[†](#TF0002){ref-type="table-fn"}
                                     LTG                 1.98 ± 1.02       \> 0.05[§](#TF0004){ref-type="table-fn"}
                                     CON                 1.83 ± 0.88       \> 0.05[\*\*](#TF0005){ref-type="table-fn"}
  Sex hormone-binding globulin       CBZ                 41.10 ± 21.50     \> 0.05[\*](#TF0001){ref-type="table-fn"}
                                     VPA                 39.70 ± 10.30     \< 0.05[†](#TF0002){ref-type="table-fn"}
                                     LTG                 20.30 ± 11.20     \< 0.05[‡](#TF0003){ref-type="table-fn"}
                                     CON                 26.70 ± 9.90      \> 0.05[§](#TF0004){ref-type="table-fn"}
  Luteinizing hormone                CBZ                 3.57 ± 0.86       \< 0.05[‡](#TF0003){ref-type="table-fn"}
                                     VPA                 2.62 ± 0.88       \> 0.05[†](#TF0002){ref-type="table-fn"}
                                     LTG                 2.94 ± 0.85       \> 0.05[††](#TF0006){ref-type="table-fn"}
                                     CON                 2.84 ± 0.87       \> 0.05[§](#TF0004){ref-type="table-fn"}
  Follicle stimulating hormone       CBZ                 4.48 ± 1.23       \> 0.05[\*](#TF0001){ref-type="table-fn"}
                                     VPA                 4.31 ± 1.87       \> 0.05[††](#TF0006){ref-type="table-fn"}
                                     LTG                 3.11 ± 0.97       \< 0.05[§](#TF0004){ref-type="table-fn"}
                                     CON                 4.29 ± 1.53       \> 0.05[\*\*](#TF0005){ref-type="table-fn"}
  Testosterone/luteinizing hormone   CBZ                 0.97 ± 0.38       \> 0.05[\*](#TF0001){ref-type="table-fn"}
                                     VPA                 156.90 ± 18.00    \< 0.05[††](#TF0006){ref-type="table-fn"}
                                     LTG                 153.20 ± 17.10    \< 0.05[†](#TF0002){ref-type="table-fn"}
                                     CON                 155.30 ± 10.4     \< 0.05[§](#TF0004){ref-type="table-fn"}
  Estradiol                          CBZ                 150.60 ± 11.60    \> 0.05[\*](#TF0001){ref-type="table-fn"}
                                     VPA                 156.90 ± 18.00    \> 0.05[†](#TF0002){ref-type="table-fn"}
                                     LTG                 153.20 ± 17.10    \> 0.05[§](#TF0004){ref-type="table-fn"}
                                     CON                 155.30 ± 10.40    \> 0.05[\*\*](#TF0005){ref-type="table-fn"}
  Prolactin                          CBZ                 229.00 ± 67.20    \> 0.05[‡](#TF0003){ref-type="table-fn"}
                                     VPA                 192.90 ± 87.50    \> 0.05[\*](#TF0001){ref-type="table-fn"}
                                     LTG                 189.60 ± 105.70   \> 0.05[§](#TF0004){ref-type="table-fn"}
                                     CON                 220.80 ± 77.00    \> 0.05[\*\*](#TF0005){ref-type="table-fn"}
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Comparison between CON and CBZ groups

Comparison between VPA and CON groups

T/LH ratio in LTG group was significantly higher than CBZ and VPA groups (P \< 0.001) but lower than control subjects (P \< 0.01). There was no significant difference in PRL and E concentration between the groups.

Discussion {#S0004}
==========

The potential effects of epilepsy on reproductive and endocrine function have been reviewed in previous studies. In 1954, Gastaut and Collomb evaluated a series of 36 patients who were mostly resident in institutions. They reported 27 of the patients to be sexually indifferent with infrequent or absent sexual contacts, dreams, and autoerotic behavior.^[@CIT0013]^ Since then, there have been frequent reports of this phenomenon, especially in relation to complex partial seizures (CPSs).^[@CIT0014]--[@CIT0019]^ There are a number of possible explanations for this observation. CPSs are associated with atrophy of the hippocampus and amygdale.^[@CIT0020]--[@CIT0022]^ These structures are of fundamental importance for such basic behavioral patterns as feeding, drinking, reproduction, and social interaction.^[@CIT0023]^ Destruction of temporal structures in humans results in marked changes in both sexual and social behaviors.^[@CIT0024]--[@CIT0028]^ However, chronic use of AEDs has some side effects on multiple organs.^[@CIT0029]^ It is noticeable that AEDs may also alter endocrine function in both men and women with epilepsy and this alteration may lead to clinically significant reproductive endocrine disorders in certain cases. In recent years, the effects of enzyme-inducing AEDs (EIAEDs) on androgen metabolism have been invoked as a possible etiologic factor. These drugs have been found to cause an increase in total T (TT) and SHBG, but a decrease in free testosterone (FT) and free androgen index (FAI) in men.^[@CIT0010],\ [@CIT0025]^ This led to the suggestion that the reduction of FT and FAI induced by AED therapy is the cause of diminished libido observed in men with epilepsy.

The reproductive endocrine effects of CBZ in men with epilepsy appear to be similar to those observed during PHT medication, except that CBZ has not been reported to be associated with elevated serum TT or E concentrations; in addition, many cross-sectional and prospective studies have reported that an increase in serum SHBG concentrations results in decreased levels of bioactive free androgens (FAI).^[@CIT0009]^ Some studies have shown that the use of CBZ is associated with a progressive increase in serum levels of SHBG which in turn results in low FAI ratios and reflect decreased serum levels of free, bioactive T in male patients.^[@CIT0028]^ This progressive change appears to cause sexual dysfunction in some men with epilepsy after long-term CBZ treatment. Low serum DHEAS levels have also been reported in men on CBZ. DHEAS is a weak androgen secreted by the adrenal cortex. The clinical significance of decreased serum DHEAS concentrations is unknown. It has been suggested that the metabolism of hormones and synthesis of hormone binding globulins is increased during medication with EIAEDs due to liver enzyme induction. No consistent abnormalities have been found in the basal or stimulated serum PRL or gonadotropin levels in men taking CBZ for epilepsy.^[@CIT0028]^

VPA is not an EIAED. However, studies have suggested that in addition to reducing serum gonadotropin levels, VPA also increases serum AND concentrations in men with epilepsy. The mechanism by which VPA alters reproductive endocrine function in men with epilepsy is unknown. VPA modifies gamma-aminobutyric acid-ergic (GABAergic) neurotransmission and could alter the secretion of gonadotropins. On the other hand, a direct effect of VPA on testicular androgen synthesis is possible. Cases of infertility have been reported in male subjects taking VPA for epilepsy. An in vitro study suggested that VPA has direct effects on sperm motility.^[@CIT0009]^ Two recent clinical studies have also shown that VPA may reduce sperm motility, increase the frequency of morphologically abnormal sperm, and be associated with small testicular size in men with epilepsy.^[@CIT0010],\ [@CIT0011]^

Conclusion {#S0005}
==========

Although the mean levels of reproductive hormones were lower in LTG group than controls, among of traditional AEDs, LTG had fewer side effects on reproductive hormones. Therefore, it is a good adjuvant and substitute drug for epilepsy control instead of CBZ and VPA.
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